Use of proven therapies in non–ST-elevation acute coronary syndromes according to evidence-based risk stratification
- 30 April 2007
- journal article
- Published by Elsevier in American Heart Journal
- Vol. 153 (4) , 493-499
- https://doi.org/10.1016/j.ahj.2007.01.001
Abstract
No abstract availableKeywords
This publication has 34 references indexed in Scilit:
- Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trialsThe Lancet, 2002
- Comparison of Two Platelet Glycoprotein IIb/IIIa Inhibitors, Tirofiban and Abciximab, for the Prevention of Ischemic Events with Percutaneous Coronary RevascularizationNew England Journal of Medicine, 2001
- Long-term mortality benefit with abciximab in patients undergoing percutaneous coronary interventionJournal of the American College of Cardiology, 2001
- The use of glycoprotein IIb/IIIa inhibitors in patients with coronary artery diseaseThe American Journal of Medicine, 2000
- Assessment of the Treatment Effect of Enoxaparin for Unstable Angina/Non–Q-Wave Myocardial InfarctionCirculation, 1999
- Enoxaparin Prevents Death and Cardiac Ischemic Events in Unstable Angina/Non–Q-Wave Myocardial InfarctionCirculation, 1999
- Inhibition of Platelet Glycoprotein IIb/IIIa with Eptifibatide in Patients with Acute Coronary SyndromesNew England Journal of Medicine, 1998
- A Comparison of Aspirin plus Tirofiban with Aspirin plus Heparin for Unstable AnginaNew England Journal of Medicine, 1998
- Inhibition of the Platelet Glycoprotein IIb/IIIa Receptor with Tirofiban in Unstable Angina and Non–Q-Wave Myocardial InfarctionNew England Journal of Medicine, 1998
- A Comparison of Low-Molecular-Weight Heparin with Unfractionated Heparin for Unstable Coronary Artery DiseaseNew England Journal of Medicine, 1997